Abstract: An electrostatic chuck includes a base having a surface on which an object is to be placed, and a through hole extending through the base, wherein a porous material containing angular ceramic particles is disposed in the through hole.

Abstract: The present invention relates to vitamin D3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.

Abstract: A first piece (13) includes a first ring portion (13b) and a second ring portion (13c) which are arranged side by side in an axial direction and an inner diameter and an outer diameter of the first ring portion (13b) are respectively larger than an inner diameter and an outer diameter of the second ring portion (13c). A second piece (16) is obtained by pressing the first piece (13) while the first piece (13) is disposed between a first set and a second set.

Abstract: An electrostatic chuck includes a base having a surface on which an object is to be placed, and a through hole extending through the base, wherein a porous material containing angular ceramic particles is disposed in the through hole.

Abstract: The electrostatic chuck includes an insulating substrate having a placement surface on which a suction target object is placed and an opposite surface provided on an opposite side to the placement surface; and a gas hole penetrating from the opposite surface to the placement surface. The gas hole has a first hole portion extending from the opposite surface toward the placement surface, a second hole portion extending from the placement surface toward the opposite surface, and a third hole portion provided between the first hole portion and the second hole portion and formed to communicate the first hole portion and the second hole portion each other. The first hole portion is provided not to overlap with the second hole portion in a plan view.

Abstract: A nutrient intake amount estimation system according to an embodiment includes: a sensor that is disposed in a toilet space, and configured to detect an excretion smell related to excretion of a user of the toilet space; an estimation unit configured to estimate an estimated nutrient intake amount that is an amount of nutrients taken by the user by using an output of an estimation model that outputs information indicating an amount of nutrients estimated to be taken by the user in accordance with an input based on an output value of the sensor; and an output unit configured to output information based on the estimated nutrient intake amount.

Abstract: With respect to the manufacture of cylindrical rolling bodies, excess material on an outside section in the radial direction and recesses in both end surfaces in the axial direction are not generated as much as possible in the intermediate material that is removed from a molding device for performing compression molding. Annular concave sections 27 are provided on the inner-circumferential surfaces 20a of molding concave sections 19a provided in a stationary-side mold 17a and a movable-side mold 18a. The stationary-side mold 17a and the movable-side mold 18a are brought close to each other in the axial direction while compressing the intermediate material 23 in a state in which both side sections in the axial direction of the intermediate material 23 are inserted into the molding concave sections 19a.

Abstract: With respect to the manufacture of cylindrical rolling bodies, excess material on an outside section in the radial direction and recesses in both end surfaces in the axial direction are not generated as much as possible in the intermediate material that is removed from a molding device for performing compression molding. Annular concave sections 27 are provided on the inner-circumferential surfaces 20a of molding concave sections 19a provided in a stationary-side mold 17a and a movable-side mold 18a. The stationary-side mold 17a and the movable-side mold 18a are brought close to each other in the axial direction while compressing the intermediate material 23 in a state in which both side sections in the axial direction of the intermediate material 23 are inserted into the molding concave sections 19a.

Abstract: A method of manufacturing a cylindrical ring member includes a step of forming a metal intermediate material having a cylindrical portion and a chamfering step by cold forging in which a normal chamfer portion is formed on an axial end peripheral edge of the cylindrical portion by pressing a radial end portion of an axial end surface of the cylindrical portion against an annular chamfering surface provided in a mold configuring a mold device. A chamfering step is performed by cold forging in a state where a preliminary chamfer portion, of which a width dimension in a radial direction is larger than a width dimension of the normal chamfer portion in a radial direction, is formed on the axial end peripheral edge of the cylindrical portion.

Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.

Abstract: The present invention relates to vitamin D3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.

Abstract: A method of manufacturing a cylindrical ring member includes a step of forming a metal intermediate material having a cylindrical portion and a chamfering step by cold forging in which a normal chamfer portion is formed on an axial end peripheral edge of the cylindrical portion by pressing a radial end portion of an axial end surface of the cylindrical portion against an annular chamfering surface provided in a mold configuring a mold device. A chamfering step is performed by cold forging in a state where a preliminary chamfer portion, of which a width dimension in a radial direction is larger than a width dimension of the normal chamfer portion in a radial direction, is formed on the axial end peripheral edge of the cylindrical portion.

Abstract: The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently.

Abstract: The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently.

Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.

Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.

Abstract: The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B—C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently.

Abstract: The present invention relates to methods for reducing body weight in an animal in need thereof via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently. Also provided are methods for increasing thermogenesis without reducing lean body mass during weight loss in an animal by administering of a therapeutically effective amount of the compounds described.

Abstract: Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition.

Abstract: The present invention relates to methods for reducing body weight in an animal in need thereof via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently. Also provided are methods for increasing thermogenesis without reducing lean body mass during weight loss in an animal by administering of a therapeutically effective amount of the compounds described.